|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DAB2 |
Gene summary for DAB2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DAB2 | Gene ID | 1601 |
| Gene name | DAB adaptor protein 2 | |
| Gene Alias | DOC-2 | |
| Cytomap | 5p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P98082 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1601 | DAB2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.86e-16 | 5.81e-01 | -0.0811 |
| 1601 | DAB2 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.91e-06 | 3.85e-01 | -0.1088 |
| 1601 | DAB2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 9.86e-17 | 5.47e-01 | -0.059 |
| 1601 | DAB2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 3.58e-02 | 2.27e-01 | -0.0179 |
| 1601 | DAB2 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.64e-04 | 2.51e-01 | 0.096 |
| 1601 | DAB2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.53e-06 | 4.11e-01 | 0.0338 |
| 1601 | DAB2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.60e-29 | 6.31e-01 | 0.0674 |
| 1601 | DAB2 | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.07e-04 | 4.16e-01 | 0.0112 |
| 1601 | DAB2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.33e-05 | 3.29e-01 | 0.0588 |
| 1601 | DAB2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.35e-08 | 2.59e-01 | 0.294 |
| 1601 | DAB2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.84e-09 | 4.11e-01 | 0.281 |
| 1601 | DAB2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.43e-05 | 2.24e-01 | 0.3859 |
| 1601 | DAB2 | A002-C-021 | Human | Colorectum | FAP | 8.00e-03 | 1.47e-01 | 0.1171 |
| 1601 | DAB2 | P2T-E | Human | Esophagus | ESCC | 2.88e-05 | 5.46e-02 | 0.1177 |
| 1601 | DAB2 | P9T-E | Human | Esophagus | ESCC | 5.94e-06 | 2.88e-01 | 0.1131 |
| 1601 | DAB2 | P16T-E | Human | Esophagus | ESCC | 2.03e-13 | 1.29e-01 | 0.1153 |
| 1601 | DAB2 | P32T-E | Human | Esophagus | ESCC | 3.62e-19 | 6.73e-01 | 0.1666 |
| 1601 | DAB2 | P37T-E | Human | Esophagus | ESCC | 2.19e-10 | 2.23e-01 | 0.1371 |
| 1601 | DAB2 | P40T-E | Human | Esophagus | ESCC | 1.61e-02 | 1.62e-01 | 0.109 |
| 1601 | DAB2 | P44T-E | Human | Esophagus | ESCC | 7.96e-06 | 3.88e-01 | 0.1096 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000698624 | Oral cavity | EOLP | response to unfolded protein | 48/2218 | 137/18723 | 1.14e-12 | 2.52e-10 | 48 |
| GO:001056325 | Oral cavity | EOLP | negative regulation of phosphorus metabolic process | 105/2218 | 442/18723 | 1.22e-12 | 2.60e-10 | 105 |
| GO:004232624 | Oral cavity | EOLP | negative regulation of phosphorylation | 94/2218 | 385/18723 | 3.58e-12 | 7.15e-10 | 94 |
| GO:000276413 | Oral cavity | EOLP | immune response-regulating signaling pathway | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
| GO:003133424 | Oral cavity | EOLP | positive regulation of protein-containing complex assembly | 67/2218 | 237/18723 | 4.77e-12 | 8.17e-10 | 67 |
| GO:004586226 | Oral cavity | EOLP | positive regulation of proteolysis | 91/2218 | 372/18723 | 7.08e-12 | 1.15e-09 | 91 |
| GO:001049825 | Oral cavity | EOLP | proteasomal protein catabolic process | 108/2218 | 490/18723 | 7.79e-11 | 9.51e-09 | 108 |
| GO:000193324 | Oral cavity | EOLP | negative regulation of protein phosphorylation | 82/2218 | 342/18723 | 2.24e-10 | 2.20e-08 | 82 |
| GO:004217626 | Oral cavity | EOLP | regulation of protein catabolic process | 90/2218 | 391/18723 | 2.92e-10 | 2.58e-08 | 90 |
| GO:003497624 | Oral cavity | EOLP | response to endoplasmic reticulum stress | 66/2218 | 256/18723 | 5.33e-10 | 4.31e-08 | 66 |
| GO:200123525 | Oral cavity | EOLP | positive regulation of apoptotic signaling pathway | 41/2218 | 126/18723 | 6.68e-10 | 5.06e-08 | 41 |
| GO:003367323 | Oral cavity | EOLP | negative regulation of kinase activity | 62/2218 | 237/18723 | 9.46e-10 | 6.75e-08 | 62 |
| GO:190336226 | Oral cavity | EOLP | regulation of cellular protein catabolic process | 64/2218 | 255/18723 | 3.10e-09 | 1.92e-07 | 64 |
| GO:000646922 | Oral cavity | EOLP | negative regulation of protein kinase activity | 56/2218 | 212/18723 | 4.15e-09 | 2.41e-07 | 56 |
| GO:0001667110 | Oral cavity | EOLP | ameboidal-type cell migration | 100/2218 | 475/18723 | 5.24e-09 | 2.85e-07 | 100 |
| GO:003133025 | Oral cavity | EOLP | negative regulation of cellular catabolic process | 64/2218 | 262/18723 | 9.72e-09 | 4.77e-07 | 64 |
| GO:001063119 | Oral cavity | EOLP | epithelial cell migration | 80/2218 | 357/18723 | 1.03e-08 | 4.97e-07 | 80 |
| GO:009013219 | Oral cavity | EOLP | epithelium migration | 80/2218 | 360/18723 | 1.52e-08 | 6.97e-07 | 80 |
| GO:190305026 | Oral cavity | EOLP | regulation of proteolysis involved in cellular protein catabolic process | 56/2218 | 221/18723 | 2.06e-08 | 8.84e-07 | 56 |
| GO:000989525 | Oral cavity | EOLP | negative regulation of catabolic process | 73/2218 | 320/18723 | 2.07e-08 | 8.84e-07 | 73 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa041446 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
| hsa041447 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
| hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| DAB2 | INCAF | Skin | ADJ | CTSL,HMGA1,CCDC80, etc. | 1.92e-01 |  |
| DAB2 | INCAF | Skin | SCCIS | CTSL,HMGA1,CCDC80, etc. | 2.45e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DAB2 | SNV | Missense_Mutation | c.1639N>A | p.Gly547Ser | p.G547S | P98082 | protein_coding | tolerated(0.28) | benign(0.043) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| DAB2 | SNV | Missense_Mutation | rs376782436 | c.1729G>A | p.Ala577Thr | p.A577T | P98082 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| DAB2 | SNV | Missense_Mutation | novel | c.1797N>A | p.Phe599Leu | p.F599L | P98082 | protein_coding | deleterious(0.03) | possibly_damaging(0.459) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DAB2 | SNV | Missense_Mutation | c.5C>T | p.Ser2Phe | p.S2F | P98082 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A0W4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DAB2 | SNV | Missense_Mutation | c.796N>G | p.Pro266Ala | p.P266A | P98082 | protein_coding | deleterious(0.05) | possibly_damaging(0.62) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DAB2 | SNV | Missense_Mutation | c.2277N>C | p.Glu759Asp | p.E759D | P98082 | protein_coding | tolerated(1) | benign(0) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| DAB2 | SNV | Missense_Mutation | novel | c.1546N>G | p.Thr516Ala | p.T516A | P98082 | protein_coding | tolerated(0.93) | benign(0) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| DAB2 | SNV | Missense_Mutation | novel | c.1931N>T | p.Gly644Val | p.G644V | P98082 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-E9-A3HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| DAB2 | insertion | Nonsense_Mutation | novel | c.1317_1318insTGACTCTTTTGCTTTTGCTCATAAAATGATGATGCATC | p.Gly440Ter | p.G440* | P98082 | protein_coding | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| DAB2 | insertion | Nonsense_Mutation | novel | c.1581_1582insACTTTGATGCTAATCAACTATTGA | p.Met527_Ala528insThrLeuMetLeuIleAsnTyrTer | p.M527_A528insTLMLINY* | P98082 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |